Formulation and evaluation of Transdermal Patch for the treatment of Migraine

Abstract

A migraine is a specific kind of headache disorder that primarily affects the head. It can range in severity from mild to severe and is often accompanied by other symptoms like vomiting, nausea, illness, dizziness that gets worse with movement, photophobia, sonophobia, severe disability, or other types of nature. Triptans that are administered intravenously can be used to treat migraines and irritated injection sites. Transdermal delivery means that the medications will be administered through the skin in a precise, regulated manner. Our study aims to identify all possible transdermal patch combination and application for the treatment of migraines. The drug rizatriptan belongs to a group of drugs known as selective serotonin receptor agonists.  It functions by constricting blood vessels in the brain, preventing the transmission of pain signals to the brain, and preventing the production of several naturally occurring compounds that produce pain, nausea, and other migraine symptoms. Verapamil belongs to the group of drugs known as calcium-channel blockers. It works by relaxing the blood vessels in order to reduce the workload of the heart. The Lambda max Rizatriptan and Verapamil is 278.9nm and 228nm respectively. They are soluble in most of the solvents. When used with verapamil, rizatriptan's transdermal patch improves patient compliance in those with hypertension. P2 patch shows the optimized results. Keywords: Migraine, Rizatriptan, Verapamil, Bioavailability, Transdermal patch.